

**e-Table: Randomized controlled surrogate end-point trials of hormone replacement therapy for the prevention of coronary artery disease**

Study	Therapy	No. of subjects	Mean duration, yr	Surrogate end point(s)	Treatment v. placebo
<b>Primary prevention</b>					
Postmenopausal Estrogen/Progestin Interventions Trial <sup>16</sup>	CEE with or without MPA	875	3	Mean change in high-density lipoprotein cholesterol level (and 95% CI), mmol/L*	CEE: 0.14 (0.12 to 0.17) CEE/MPA(cyc): 0.04 (0.01 to 0.07) CEE/MPA(con): 0.03 (0.00 to 0.06) CEE/MP(cyc): 0.11 (0.08 to 0.13) v. -0.03 (-0.06 to -0.01)
				Mean change in low-density lipoprotein cholesterol level (and 95% CI), mmol/L*	CEE: -0.37 (-0.43 to -0.31) CEE/MPA(cyc): -0.46 (-0.52 to -0.40) CEE/MPA(con): -0.43 (-0.49 to -0.37) CEE/MP(cyc): -0.38 (-0.44 to -0.32) v. -0.11 (-0.17 to -0.05)
Estrogen in the Prevention of Atherosclerosis trial <sup>18</sup>	Estradiol-17 $\beta$	222	2	Mean annual change in intima media thickness of common carotid artery, mm†	-0.0017 v. 0.0036
<b>Secondary prevention</b>					
Estrogen Replacement and Atherosclerosis trial <sup>17</sup>	CEE with or without MPA	309	3.2	Mean change in minimal coronary artery diameter ( $\pm$ SE), mm‡	CEE: -0.09 ( $\pm$ 0.02) CEE/MPA: -0.12 ( $\pm$ 0.02) v. -0.09 ( $\pm$ 0.02)
Women's Angiographic Vitamin and Estrogen Trial <sup>9</sup>	CEE + MPA	423	2.8	Mean annual change in minimal coronary artery diameter, mm§	-0.027 v. 0.007

Note: CEE = conjugated equine estrogen, MPA = medroxyprogesterone acetate, MP = micronized progesterone, cyc = cyclic administration (days 1-12 of each month), con = continuous administration, CI = confidence interval, SE = standard error.

\**p* (Bonferroni; nominal) < 0.01.

†*p* = 0.046.

‡*p* = 0.97 (CEE v. placebo) and 0.38 (CEE/MPA v. placebo).

§*p* = 0.20.